%0 Journal Article
%T Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor¨CInduced Enteritis
%A Aline Charabaty
%A Charoen Mankongpaisarnrung
%A Jay C. Zeck
%A Michael B. Atkins
%A Pietro Diana
%J Archive of "ACG Case Reports Journal".
%D 2018
%R 10.14309/crj.2018.17
%X We report a 62-year-old white woman with metastatic choroidal melanoma who developed immune checkpoint inhibitor (ICI)-induced enteritis and grade 3 diarrhea refractory to steroids and infliximab. Her diarrhea quickly resolved after infusion of vedolizumab, and the patient was able to taper down steroids. VedolizumabĄ¯s mechanism of action and its gut specificity have the potential to reverse immune-induced enterocolitis without neutralizing or reversing the therapeutic benefit of ICI on the malignancy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830540/